Ionis Pharmaceuticals Reports Strong Q1 2026 with 87% Revenue Growth and Reduced Net Loss
IONS has more than doubled off its 52-week low of $29.42.
Summary
Ionis Pharmaceuticals delivered robust first-quarter results, driven by significant increases in product sales and collaborative R&D revenue, leading to a substantial reduction in net loss.
Key Events · Earnings and Guidance · IONS
-
Revenue Surge
Total revenue increased 87% year-over-year to $246.1 million in Q1 2026, compared to $131.6 million in Q1 2025.
-
Reduced Net Loss
Net loss decreased to $92.5 million in Q1 2026 from $146.9 million in the prior year quarter.
-
Product Commercialization Success
TRYNGOLZA sales grew to $27.1 million, and DAWNZERA generated $15.9 million in its first full quarter of sales.
-
Significant R&D Milestones
The company earned $95 million in milestone payments, including $50 million from Roche for a Phase 1 Alzheimer's disease trial and $30 million from GSK for bepirovirsen regulatory filings.
Analysis · IONS · Life Sciences
Ionis Pharmaceuticals demonstrated strong operational execution in Q1 2026, significantly boosting its financial performance. The substantial 87% year-over-year revenue growth was primarily fueled by the successful commercialization of new products like TRYNGOLZA and DAWNZERA, alongside robust collaborative R&D revenue from key partners. The company achieved $95 million in milestone payments, highlighting the continued progress and value of its pipeline, including advancements for Alzheimer's disease and chronic hepatitis B programs. This strong revenue performance contributed to a notable reduction in net loss. While operating cash flow showed a significant outflow, a large portion was attributed to the pre-funding of the $432.5 million convertible note repayment, which was successfully completed in April 2026, and $200 million of the escrow will be returned in Q2, improving future liquidity. The company's strategic focus on advancing its wholly-owned and partnered medicines, coupled with its strong financial foundation, positions it for continued growth and potential future product launches.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IONS was trading at $73.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.1B. The 52-week trading range was $29.42 to $86.74. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.